HepaTx, a pre-clinical stage biotechnology company dedicated to the development of transformative therapies for liver diseases, announced today that Julio Gutierrez, MD has joined their Clinical Advisory Board.
Palo Alto, CA – San Diego, CA - HepaTx, a pre-clinical stage biotechnology company dedicated to the development of transformative therapies for liver diseases, announced today that Julio Gutierrez, MD has joined their Clinical Advisory Board. Dr. Gutierrez is a highly respected transplant hepatologist and liver disease expert with extensive experience in basic, translational, computational, and clinical research. His expertise and unique skillset will be instrumental in supporting the development of HepaTx’s innovative therapeutic pipeline.
Dr. Julio Gutierrez is a Transplant Hepatologist at Scripps Center for Organ and Cell Transplant. He is the Director of the Care Pathway and the Former Director of the Liver Tumor Program at the University of Texas Health Science Center at San Antonio (UTHSCA), and the Medical Director of Liver Transplant at St. Vincent. While at Mount Sinai, Dr. Gutierrez developed a methodology to harvest human macrophages from ascites and primary human hepatocytes from explants for cell culture. As attending faculty at UTHSCA, UCSD, and Scripps Clinic, Dr. Gutierrez has conducted federally funded research and pharma-sponsored clinical trials to investigate novel therapeutics for hepatitis B & C, fatty liver, T2DM, primary biliary cholangitis, hepatocellular carcinoma, and cirrhosis. Dr. Gutierrez is an industry partner and has worked both on the CRO and sponsor side. He has deep experience as an investigator, and knowledge in the entire cycle of clinical development, including study design, study execution, monitoring, analysis, regulatory interactions, study reporting, and publication.
“Dr. Gutierrez brings a wealth of expertise and experience to our team,” said Eric Schuur, Chief Executive Officer of HepaTx. “His deep understanding of liver diseases and clinical development, as well as his extensive experience as an investigator, will be invaluable as we continue to advance our innovative therapeutic pipeline.”
“I am excited to join the HepaTx Clinical Advisory Board and work with the team to develop innovative therapies for liver diseases,” said Dr. Gutierrez. “I look forward to leveraging my expertise and experience to support HepaTx’s efforts to improve the lives of patients suffering from liver diseases.”
About HepaTx
HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter and LinkedIn.
Contact:
HepaTx
Claudia Preziosi
cpreziosi@hepatx.com